Ramsey-based ADMA Biologics Inc. announced Tuesday the closing of its previously announced initial public offering of 3.35 million shares of its common stock at a public offering price of $8.50 per share.
According to the announcement, aggregate net proceeds to ADMA, after deducting underwriting discounts and commissions, will be approximately $26.5 million. Oppenheimer & Co. acted as sole book-running manager for the offering, first priced last week. Ladenburg Thalmann & Co. Inc., Maxim Group LLC and Laidlaw & Co. Ltd. acted as co-managers.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy